Coupling of liquid chromatography/tandem mass spectrometry and liquid chromatography/solid-phase extraction/NMR techniques for the structural identification of metabolites following in vitro biotransformation of SUR1-selective ATP-sensitive potassium channel openers

Drug Metabolism and Disposition

Volumn 38, Issue 2, 2010, Pages 232-240

  Gillotin, Florian ^a   Chiap, Patrice ^a   Frédérich, Michel ^b   Van Heugen, Jean Claude ^a   Francotte, Pierre ^b   Lebrun, Philippe ^c   Pirotte, Bernard ^b   De Tullio, Pascal ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 3 ( 3 PENTYLAMINO) 4H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 7 CHLORO 3 ISOPROPYLAMINO 4H 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; BENZOTHIADIAZINE DERIVATIVE; BPDZ 157; PHENOBARBITAL; POTASSIUM CHANNEL STIMULATING AGENT; SUR1 SELECTIVE ATP SENSITIVE POTASSIUM CHANNEL OPENER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CROSS COUPLING REACTION; CYTOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LIVER MICROSOME; MAMMAL; METABOLITE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BENZOTHIADIAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC S-OXIDES; DIAZOXIDE; HUMANS; ION CHANNEL GATING; ISOMERISM; KATP CHANNELS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MEMBRANE TRANSPORT MODULATORS; METABOLIC DETOXICATION, PHASE I; MICROSOMES, LIVER; PHENOBARBITAL; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DRUG; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY;

MAMMALIA; RATTUS;

EID: 76149084797     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028928     Document Type: Article

References (28)

1. Ardehali H and O'Rourke B (2005) Mitochondrial K(ATP) channels in cell survival and death. J Mol Cell Cardiol 39:7-16.
2. Babenko AP, Aguilar-Bryan L, and Bryan J (1998) A view of sur/KIR6.X, KATP channels. Annu Rev Physiol 60:667-687.
3. Ballanyi K (2004) Protective role of neuronal KATP channels in brain hypoxia. J Exp Biol 207:3201-3212.
4. Barbuch RJ, Campanale K, Hadden CE, Zmijewski M, Yi P, O'Bannon DD, Burkey JL, and Kulanthaivel P (2006) In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy. Drug Metab Dispos 34:213-224.
5. Billman GE (2008) The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Ther 120:54-70.
6. Clarke NJ, Rindgen D, Korfmacher WA, and Cox KA (2001) Systematic LC/MS metabolite identification in drug discovery. Anal Chem 73:430A-439A.
7. Clarkson C, Staerk D, Hansen SH, and Jaroszewski JW (2005) Hyphenation of solid-phase extraction with liquid chromatography and nuclear magnetic resonance: application of HPLCDAD-SPE-NMR to identification of constituents of Kanahia laniflora. Anal Chem 77:3547-3553.
8. Corcoran O and Spraul M (2003) LC-NMR-MS in drug discovery. Drug Discov Today 8:624-631.
9. de Tullio P, Becker B, Boverie S, Dabrowski M, Wahl P, Antoine MH, Somers F, Sebille S, Ouedraogo R, Hansen JB, et al. (2003) Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2, 4-benzothiadiazine 1,1-dioxides. J Med Chem 46:3342-3353.
10. de Tullio P, Boverie S, Becker B, Antoine MH, Nguyen QA, Francotte P, Counerotte S, Sebille S, Pirotte B, and Lebrun P (2005) 3-Alkylamino-4H-1,2,4- benzothiadiazine 1,1-dioxides as ATP-sensitive potassium channel openers: effect of 6,7-disubstitution on potency and tissue selectivity. J Med Chem 48:4990-5000.
11. Hambrock A, Löffler-Walz C, Kloor D, Delabar U, Horio Y, Kurachi Y, and Quast U (1999) ATP-Sensitive K+ channel modulator binding to sulfonylurea receptors SUR2A and SUR2B: opposite effects of MgADP. Mol Pharmacol 55:832-840.
12. Hansen JB (2006) Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 13:361-376.
13. Inagaki N, Gonoi T, Clement JP 4th, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, and Bryan J (1995) Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270:1166-1170.
14. Ko EA, Han J, Jung ID, and Park WS (2008) Physiological roles of K+ channels in vascular smooth muscle cells. J Smooth Muscle Res 44:65-81.
15. Lawson K (1996) Potassium channel activation: a potential therapeutic approach? Pharmacol Ther 70:39-63.
16. Lebrun P, Antoine MH, Ouedraogo R, Herchuelz A, de Tullio P, Delarge J, and Pirotte B (1997) Pyridothiadiazines as potent inhibitors of glucose-induced insulin release. Adv Exp Med Biol 426:145-148.
17. Miki T, Nagashima K, and Seino S (1999) The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells. J Mol Endocrinol 22:113-123.
18. Oliveira EJ and Watson DG (2000) Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics. Biomed Chromatogr 14:351-372.
19. Pirotte B, Antoine MH, de Tullio P, Hermann M, Herchuelz A, Delarge J, and Lebrun P (1994) A pyridothiadiazine (BPDZ 44) as a new and potent activator of ATP-sensitive K+ channels. Biochem Pharmacol 47:1381-1386.
20. Raffa LLL and Grana E (1965) Azione cardiovasolare di derivati del 1,2,4-benzotiadiazin-1,1-diossido, nota II. Il Farmaco 20:647-661.
21. Rasmussen SB, Sørensen TS, Hansen JB, Mandrup-Poulsen T, Hornum L, and Markholst H (2000) Functional rest through intensive treatment with insulin and potassium channel openers preserves residual beta-cell function and mass in acutely diabetic BB rats. Horm Metab Res 32:294-300.
22. Sandvoss M, Bardsley B, Beck TL, Lee-Smith E, North SE, Moore PJ, Edwards AJ, and Smith RJ (2005) HPLC-SPE-NMR in pharmaceutical development: capabilities and applications. Magn Reson Chem 43:762-770.
23. Silva Elipe MV (2003) Advantages and disadvantages of nuclear magnetic resonance spectroscopy as a hyphenated technique. Anal Chim Acta 497:1-25.
24. Simpson AJ, Tseng LH, Simpson MJ, Spraul M, Braumann U, Kingery WL, Kelleher BP, and Hayes MH (2004) The application of LC-NMR and LC-SPE-NMR to compositional studies of natural organic matter. Analyst 129:1216-1222.
25. Tatsis EC, Boeren S, Exarchou V, Troganis AN, Vervoort J, and Gerothanassis IP (2007) Identification of the major constituents of Hypericum perforatum by LC/SPE/NMR and/or LC/MS. Phytochemistry 68:383-393.
26. Waxman DJ and Azaroff L (1992) Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 281 (Pt 3):577-592.
27. Wilson SR, Malerød H, Petersen D, Simic N, Bobu MM, Rise F, Lundanes E, and Greibrokk T (2006) Short communication controlling LC-SPE-NMR systems. J Sep Sci 29:582-589.
28. Yang Z (2006) Online hyphenated liquid chromatography-nuclear magnetic resonance spectroscopy-mass spectrometry for drug metabolite and nature product analysis. J Pharm Biomed Anal 40:516-527.